- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
|Research Code||Therapeutic Area||Indication||Pre-Clinical||Phase I||Phase II||Phase III||NDA||Market||More|
ON101 is a first-in-class new drug targeting the subsets of macrophages to promote healing of the chronic wounds. It has been demonstrated with the superior efficacy to the standard care dressing in a Phase 3 MRCT completed in the US, Taiwan, and China. It has been marketed under the trade name FESPIXON® in Taiwan since June 2021 and been granted the Fast Track designation by the US FDA in March 2021. Multiple NDA submissions of ON101 to Asian health authorities are underway
FB825 is a first-in-class antibody targeting IgE B cells for the treatment of allergic diseases. It specifically binds to the CεmX domain on the membrane-bound IgE B cells and induces the apoptosis and ADCC of the targeted cells
FB704A is a fully human monoclonal antibody that inhibits IL-6/IL-6R signaling pathway by neutralizing IL-6. IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in many cancers and immune disorders.
OB318 is a new drug for hepatocellular carcinoma (HCC) which is the most common type of liver cancers, accounting for 90% of the cases
FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for asthma. It has been discovered and developed from Oneness-owned antibody library
SNS812 is a first-in-class siRNA new drug for COVID-19 infection. It specifically targets the highly conserved region of SARS-COV-2 genome to inhibit virus replication and eliminate viruses in cells.